Print Page | Close Window
Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015
DateTitle 
04/23/19AtriCure Announces First Patient Enrollment in the DEEP IDE Trial Restart
The trial is intended to establish the safety and effectiveness of a dual epicardial and endocardial ablation procedure for patients with persistent or long-standing persistent atrial fibrillation MASON, Ohio--(BUSINESS WIRE)--Apr. 23, 2019-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatment for atrial fibrillation (Afib) and left atrial appendage management, today announced the restart of the Dual Epicardial and Endocardial ... 
Printer Friendly Version
04/04/19AtriCure to Announce First Quarter 2019 Financial Results
MASON, Ohio--(BUSINESS WIRE)--Apr. 4, 2019-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its first quarter 2019 financial results on Thursday, April 25, 2019. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, April 25, 2019 to discuss its first quarter 2019 financial re... 
Printer Friendly Version
04/01/19AtriCure to Present at the Needham & Company’s 18th Annual Healthcare Conference
MASON, Ohio--(BUSINESS WIRE)--Apr. 1, 2019-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it will present at the Needham & Company’s 18th Annual Healthcare Conference in New York on Wednesday, April 10, 2019. Management is scheduled to present at 3:30 p.m. Eastern Time. A live audio webcast of the presentation may be access... 
Printer Friendly Version
02/28/19AtriCure Reports Fourth Quarter and Full Year 2018 Financial Results
2018 Worldwide revenue of $201.6 million – an increase of 15.4% year over year 2018 U.S. revenue of $162.1 million – an increase of 17.2% year over year 2018 International revenue of $39.5 million – an increase of 8.7% year over year MASON, Ohio--(BUSINESS WIRE)--Feb. 28, 2019-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) ... 
Printer Friendly Version
02/19/19AtriCure Announces The Society of Thoracic Surgeons Has Endorsed the Company’s Advanced Ablation Courses in the United States
Endorsement complements the company’s ongoing commitment to physician education MASON, Ohio--(BUSINESS WIRE)--Feb. 19, 2019-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatment for atrial fibrillation (Afib) and left atrial appendage management, today announced that The Society of Thoracic Surgeons (STS) has endorsed its Advanced Ablation course for both physicians and fellows. The course provides surgeons and other medic... 
Printer Friendly Version
02/12/19AtriCure Announces Launch of the cryoICE® cryoSPHERE™ Probe
cryoSPHERE probe launched in United States, designed exclusively for post-operative pain block MASON, Ohio--(BUSINESS WIRE)--Feb. 12, 2019-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management (LAAM), today announced that it has launched the cryoICE® cryoSPHERE™ probe in the United States. The cryoSPHERE probe is the first device in the cryoICE family solely dedic... 
Printer Friendly Version
02/05/19AtriCure Announces the First Patient Enrolled in the ICE-AFIB™ Clinical Trial
Trial will evaluate the safety and effectiveness of AtriCure’s cryoICE® Ablation System for the treatment of persistent and long-standing persistent atrial fibrillation in open concomitant cardiac surgery MASON, Ohio--(BUSINESS WIRE)--Feb. 5, 2019-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatment for atrial fibrillation (Afib) and left atrial appendage management, today announced the first patient was treated in the ICE-AFIB™... 
Printer Friendly Version
02/04/19AtriCure to Announce Fourth Quarter and Full Year 2018 Financial Results
MASON, Ohio--(BUSINESS WIRE)--Feb. 4, 2019-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its fourth quarter and full year 2018 financial results on Thursday, February 28, 2019. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, February 28, 2019 to discuss its fourth quarter an... 
Printer Friendly Version
01/07/19AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2018
MASON, Ohio--(BUSINESS WIRE)--Jan. 7, 2019-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced preliminary financial results for the fourth quarter and full year 2018 and provided 2019 financial guidance. Preliminary, unaudited revenue for fourth quarter 2018 is expected to be approximately $52.9 million, reflecting growth of approximately 15... 
Printer Friendly Version